Back

Complementary prognostic value of nonalcoholic fatty liver disease and cardiovascular-kidney-metabolic syndrome for major adverse cardiovascular and liver events: a prospective cohort study

29 August 2026 (15:00 - 15:15)
Organised by: Logo
Congress Presentation Part of: Young Investigator Award Session in Preventive Cardiology Metabolic Syndrome, Insulin, Insulin Resistance ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Ying Xiao

State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular D, Beijing (China)

3 More presentations in this session

Presentation thumbnail
High-dose vs standard-dose influenza vaccine in older adults according to diabetes status, a prespecified analysis of the FLUNITY-HD study
Doctor K. Hosseini (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Accelerometer-derived 24-hour movement profiles and risk of cardiovascular disease and mortality: a prospective study of 76,778 UK Biobank participants
Miss Y. Zhao (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Sleep Insufficiency as a Determinant of Residual Inflammatory Risk and Major Cardiovascular Events in Statin-Treated Individuals
Doctor S. Abohashem (Boston, US)
Abstract Slides Video

Access the full session

Session thumbnail
Young Investigator Award Session in Preventive Cardiology
Video

The Event

Event poster

ESC Congress 2026

29 August 2026 15:00 CET
You may be interested in
thumbnail
Congress Presentation
Cardiovascular-kidney-liver-metabolic-health:a population-based study on the prognostic impact of the coexistence of metabolic dysfunction-associated steatotic liver disease and chronic kidney disease
30 August 2025
thumbnail
Congress Presentation
New therapeutic targets for liver-heart crisis
29 August 2026
thumbnail
Congress Presentation
The floor is yours: bring your questions on management of cardiovascular-kidney-metabolic syndrome - expert panel
30 August 2025
thumbnail
Congress Presentation
Fatty liver disease as risk factors for the clinical expression of hypertrophic cardiomyopathy
31 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources